Micromet Achieves Milestone In BiTE™ Research Collaboration With MedImmune, Inc.

Micromet AG has achieved a milestone in its collaboration with MedImmune, Inc. for the development of new BiTE™ therapeutics. In the context of the collaboration, Micromet generated BiTE™ molecules against an oncology target proprietary to MedImmune. Both companies successfully tested them for anti-tumor activity in preclinical studies. The preclinical milestone triggered an undisclosed proof-of-concept payment from MedImmune to Micromet.

Back to news